From April 10th to 11th, the 11th International Bio-Medical Technology Exhibition (BioCon China Expo 2024) was grandly held in Beijing. As a strategic partner of the BioCon Awards ceremony, Frost & Sullivan (referred to as 'Frost & Sullivan') jointly released the 'Top 10 Innovative Companies with Annual Investment Value' list with the organizer, Shangtu Pharmaceutical News, and proudly presented it at the award ceremony.
Nanjing Nuoyuan Medical Devices Co., Ltd. has stood out among many leaders in the biomedical field and has been awarded the title of 'Enterprise with Innovative Investment Value for the Year'. This honor signifies Nanjing Nuoyuan Medical Devices Co., Ltd.'s remarkable achievements and high recognition within the industry.At the award ceremony, witnessed by numerous guests and industry peers, Mr. Zheng Yubo, General Manager of Guosheng Capital, presented the Chairman Cai Huiming of Nuoyuan Medical with the "Annual Investment Value Innovation Enterprise" trophy and certificate.
Acceptance Speech
Chairman Cai Huiming stated during the award presentation that Nuoyuan Medical is a national high-tech enterprise with continuous innovation capabilities, integrating the research, development, production, and sales of high-end medical devices and innovative targeted contrast agents. The company focuses on providing full-chain solutions for precise tumor diagnosis and treatment, concentrating on core technologies such as computer-aided drug molecular design (CADD), AI-assisted drug design, molecular fluorescence, Raman spectroscopy, and artificial intelligence.
The company leverages its profound accumulation in drug research and development to develop a broad-spectrum fluorescent contrast agent, "Indocyanine Green," with international first-class quality. At the same time, the company has applied AI-assisted and CADD technologies to develop a variety of original targeted fluorescent contrast agents for multiple typical tumor receptors, including folic acid receptor (FRα), epidermal growth factor receptor (EGFR), mesenchymal-epithelial transition factor (cMET), vascular endothelial growth factor receptor (VEGFR), and passive targeted broad-spectrum agents, totaling five major series under research. Among them, the folic acid receptor (FRα) targeted probe NY-FR-07 belongs to the best-in-class drugs, featuring higher stability and tumor specificity. Currently, it is undergoing NMPA and FDA new drug clinical trial application (IND) filings and plans to conduct multi-center clinical trials in areas such as non-small cell lung cancer and ovarian cancer. The other four categories belong to first-in-class drugs, with the preparation for drugs being basically completed, and safety studies are currently underway.
At the same time, the company is a strategic partner of international leading companies such as B.Braun Melsungen and is currently advancing the registration of related products in China, the US, Europe, and international market sales. The company has also completed multiple system certifications such as 13485/9001, and several products are undergoing FDA registration in the US and CE certification in the EU.
The recognition of 'Annual Investment Value Innovative Enterprise' is not only an acknowledgment of the company's achievements but also an encouragement and expectation for its future development. Nuoyuan Medical will continue to adhere to the innovation-driven development strategy, intensify research and development of innovative targeted probes and high-end medical devices, promote product upgrades, and bring more high-quality medical solutions to the industry.
Industry evaluation
The award received by Nuoyuan Medical has been widely recognized in the industry. The company's research and development achievements in the field of innovative targeted probes and high-end medical devices, as well as its close cooperation with domestic and international universities and research institutions, demonstrate strong innovation capabilities and market competitiveness. This award further proves the company's innovation strength and development potential in the biopharmaceutical industry.
Future Outlook
With this award, Nuoyuan Medical will be more determined to continue on the path of technological innovation.
Nuoyuan Medical has established a mature 'production, education, research, medical practice, testing, and finance' integrated technological innovation model. Relying on universities and research institutions, it has built multiple technical platforms in molecular fluorescence imaging and its supporting contrast agents. In the future, the company will continue to deepen its close cooperation with universities and research institutions, build a series of technical platforms, provide strong technical support for the company's innovative development, and be based on continuous innovation and excellent products. It will strive to continuously promote the overall progress of China's biopharmaceutical industry and provide better medical solutions for clinical practice, taking market demand as the premise and continuous innovation and outstanding products as the foundation.
Conclusion
The award by Nuoyuan Medical is a reflection of the innovative vitality in China's biopharmaceutical industry and a beautiful wish for the company's future development. The company will focus on the pain points and needs in tumor diagnosis and treatment clinical practice, align with national innovation strategies, continuously promote international market expansion and cooperation, solidly advance the development of a series of internationally advanced medical equipment and contrast agents, strive to become a leader in precision medicine technology, and contribute more Chinese wisdom and strength to global health initiatives.
